

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

FITC anti-human/mouse Granzyme B Recombinant

RRID:AB_2687030

Type: Antibody

Proper Citation

BioLegend Cat# 372206, RRID:AB_2687030

Antibody Information

URL: http://antibodyregistry.org/AB_2687030

Proper Citation: BioLegend Cat# 372206, RRID:AB_2687030

Target Antigen: Granzyme B

Host Organism: mouse

Clonality: recombinant monoclonal

Comments: Applications: ICFC

Antibody Name: FITC anti-human/mouse Granzyme B Recombinant

Description: This recombinant monoclonal targets Granzyme B

Target Organism: Human, Mouse

Clone ID: Clone QA16A02

Antibody ID: AB_2687030

Vendor: BioLegend

Catalog Number: 372206

Alternative Catalog Numbers: 372205

Record Creation Time: 20231110T034045+0000

Record Last Update: 20260829T194847+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human/mouse Granzyme B Recombinant.

No alerts have been found for FITC anti-human/mouse Granzyme B Recombinant.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 28 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Dong Z, et al. (2026) Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor. *Cell host & microbe*.

Sun L, et al. (2026) An SPP1-SOCS1 pathway constrains interferon responses in tumor-associated macrophages and shapes an immunosuppressive tumor microenvironment. *Immunity*, 59(5), 1422.

Pang J, et al. (2026) Law-NQO1 redox boosts the pentose phosphate pathway to confer stem-like properties and antitumor durability in effector CD8+ T cells. *Cell chemical biology*, 33(3), 321.

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment. *Cancer immunology research*, 14(5), 718.

Kelly B, et al. (2026) Sulfur partitioning from cysteine controls T cell proliferation and effector function. *Cell*, 189(12), 3669.

Steinberg M, et al. (2025) Cannabidiol directly targets the immunosuppressive activity of regulatory myeloid cells in tumors. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 192, 118697.

Tang WW, et al. (2025) A microRNA-regulated transcriptional state defines intratumoral CD8+ T cells that respond to immunotherapy. *Cell reports*, 44(2), 115301.

Wang X, et al. (2025) Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor-Ligand Interactions That Instructs Intratumoral CD8+ T-cell Activity. *Cancer research*, 85(2), 277.

Gao Y, et al. (2025) Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy. *Cell reports. Medicine*, 6(11), 102434.

Zhao Z, et al. (2025) Sickle cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity. *Immunity*, 58(6), 1484.

Fan AE, et al. (2025) STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition. *Molecular cancer therapeutics*, 24(3), 419.

Yu H, et al. (2025) UDP-GlcUA triggers PKR kinase activity to promote liquid-liquid phase separation of TOP2A and enhances radioimmunotherapy resistance. *Molecular cell*, 85(21), 3913.

Zhang Z, et al. (2024) Malic enzyme 2 maintains metabolic state and anti-tumor immunity of CD8⁺ T cells. *Molecular cell*, 84(17), 3354.

Jiang H, et al. (2024) Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12. *Cell reports. Medicine*, 101874.

Clutton GT, et al. (2024) CD3 downregulation identifies high-avidity human CD8 T cells. *Clinical and experimental immunology*, 215(3), 279.

Cheng J, et al. (2023) Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8⁺ T cells in the tumor microenvironment. *Cell metabolism*, 35(6), 961.

Piper M, et al. (2023) Simultaneous targeting of PD-1 and IL-2R α with radiation therapy inhibits pancreatic cancer growth and metastasis. *Cancer cell*, 41(5), 950.

Camargo CP, et al. (2023) Adhesion analysis via a tumor vasculature-like microfluidic device identifies CD8⁺ T cells with enhanced tumor homing to improve cell therapy. *Cell reports*, 42(3), 112175.

Liu H, et al. (2022) Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates Fc γ R-independent GITR agonism and antitumor activity. *Cell reports. Medicine*, 3(6), 100660.

Takahashi F, et al. (2022) Immune-mediated neurodegenerative trait provoked by multimodal derepression of long-interspersed nuclear element-1. *iScience*, 25(5), 104278.